Moreover, a genomic region containing CCT2 was reported to be amplified in breast cancer, and further shown to be amplified and/or overexpressed in approximately 13% of human breast cancers analyzed as part of the Tumor Genome Atlas (TCGA) project. This evidence concerns the gene CCT2 and breast carcinoma.